Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 1,719 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positive control Clear all

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Fort Myers, Florida • Chicago, Illinois • Goshen, Indiana + 7 more

Conditions: Celiac Disease
Interventions: Mucosal Impedance Catheter, Blood sample; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Colorectal Carcinoma, Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 9 more

Conditions: Inflammatory Bowel Disease, Depression
Interventions: Cognitive Behavioral Therapy, Supportive Non-directive Therapy (SNDT); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 9 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Human Immunodeficiency Virus
Interventions: HealthMindr Application, Waitlist; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Atlanta, Georgia • Detroit, Michigan • New York, New York

Conditions: Unsafe Sex
Interventions: 1-session of telephone-administered motivational interviewing, 4-session telephone-administered motivational interviewing; Behavioral
Lead sponsor: Ohio University College of Osteopathic Medicine; Other
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Middle Aged
Interventions: MASTERY, Attentional Control; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 64 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteer
Interventions: Placebo RO4602522, RO4602522, moxifloxacin, moxifloxacin placebo; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Sepsis
Interventions: Suspected Sepsis Group - Diagnostic Measurements, Control Group - Diagnostic Measurements; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more

Conditions: Physical Activity
Interventions: HAIL Online Platform, Fit and Strong! Program; Other · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Sinusitis
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections, Crack Cocaine Use, Risky Sexual Behavior
Interventions: Prevention Care Advocate; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: dapsone gel, dapsone gel vehicle, sodium lauryl sulfate, Normal saline; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 237 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Advanced Lung Disease, Lung Transplant, Extracorporeal Membrane Oxygenation
Interventions: MRP and NMES(neuromuscular electric stimulation), Standard of Care; Device · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Respiratory Distress Syndrome in Premature Infant
Interventions: AeroFact, nCPAP; Drug · Other
Lead sponsor: Aerogen Pharma Limited; Industry
Eligibility: 26 Weeks to 31 Weeks
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 37
States / cities: Little Rock, Arkansas • Berkeley, California • Orange, California + 27 more

Conditions: Hepatitis C
Interventions: Linkage Navigation, Clinician Referral; Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 177Lu-TLX591, Enzalutamide, Abiraterone, Docetaxel; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more

Conditions: COVID-19 Testing Behaviors
Interventions: Text message-based education intervention, Historical Control; Behavioral · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 89 Years
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Brownsville, Texas • Houston, Texas • Tyler, Texas

Conditions: Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alcohol Use Disorder, Alcohol Dependence, Drug Dependence
Interventions: DynamiCare Motivation Support Program, Untreated or Routine Care Control Group; Combination Product · Other
Lead sponsor: DynamiCare Health; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: HIV CTL MEP 1000 micrograms, 19 months per subject; Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 10
States / cities: Sacramento, California • Denver, Colorado • Chicago, Illinois + 6 more

Conditions: Breast Cancer
Interventions: Enzalutamide, exemestane, Placebo (for enzalutamide); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 89
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more

Conditions: Alzheimer Disease
Interventions: BMS-708163, Placebo, Moxifloxacin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Assessment of Duodenal Epithelial Integrity in Celiac Disease With Mucosal Impedance

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Reducing Depressive Symptoms in Physically Ill Youth

Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)

Telephone-delivered Behavioral Interventions to Reduce Risky Sexual Behavior in HIV-positive Late Middle-age and Older Adults

Text Messaging to Increase Activity in Midlife

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Healthy Activities Improve Lives (HAIL)

Genetic Factors in Chronic Sinusitis

Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users

Dermal Tolerability of Dapsone Gel in Healthy Volunteers

Progressive Rehabilitation Therapy in Patients With Advanced Lung Disease

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

The DETECT HCV Linkage to Care Trial

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

Tech-Enabled CM for AUD at Scale

Study Evaluating Vaccine in Adults With HIV

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects